Revolution Medicines (NASDAQ:RVMD) Releases Quarterly Earnings Results, Misses Expectations By $0.46 EPS

Key Points

• Daraxonrasib produced an unprecedented benefit in RASolute 302, meeting primary and key secondary endpoints with a 60% reduction in risk of death versus chemotherapy and median overall survival >1 year, and the company plans to submit an NDA, start an expanded access program and present data at ASCO.
• Revolution Medicines significantly strengthened its liquidity via a historic $2 billion dual‑tranche capital raise and reported roughly $1.9 billion in cash at quarter end (plus $2.1 billion net proceeds in April), positioning it to advance multiple RAS(ON) programs.
• The company missed expectations, reporting ($2.29) EPS versus a ($1.83) estimate (a $0.46 miss), as operating costs surged—Q1 stock‑based comp rose sharply and full‑year GAAP operating expense guidance was raised to $1.7 billion to $1.8 billion—contributing to a Q1 net loss of $453.8M.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($2.29) EPS for the quarter, missing the consensus estimate of ($1.83) by ($0.46), FiscalAI reports. During the same period in the prior year, the business earned ($1.13) EPS.

Here are the key takeaways from Revolution Medicines' conference call:

• Daraxonrasib delivered an unprecedented benefit in RASolute 302, meeting primary and key secondary endpoints with a 60% reduction in risk of death versus chemotherapy and a median overall survival exceeding one year; the company intends to submit an NDA, has FDA approval to start an expanded access program, and will present detailed data in an ASCO plenary.
• The company significantly strengthened its balance sheet with an historic $2 billion dual-tranche capital raise and reported $1.9 billion in cash at quarter end (plus $2.1 billion net proceeds in April), positioning it to advance four clinical-stage RAS(ON) inhibitors and next-generation programs.
• Operating costs rose sharply—Q1 stock-based compensation was $87.3M (vs. $25.1M a year ago) after a program modification—and RevMed raised full-year stock-based comp guidance by ~$80M, now expecting GAAP operating expenses of $1.7 billion to $1.8 billion, contributing to a Q1 net loss of $453.8M.
• The development plan is broad: multiple registrational trials are underway or planned across pancreatic, NSCLC, and colorectal cancer (including expansions of RASolve 301 and initiation of RASolute 303/304/305/308/309), and early-stage programs like RM-055 (catalytic RAS(ON) inhibitor) and RMC-5127 are progressing toward first-in-human studies.

Revolution Medicines Stock Up 2.6%

Shares of NASDAQ:RVMD traded up $3.86 during midday trading on Wednesday, hitting $151.07. 2,945,056 shares of the company's stock were exchanged, compared to its average volume of 4,575,561. The company has a current ratio of 7.14, a quick ratio of 7.14 and a debt-to-equity ratio of 0.16. The stock has a 50 day moving average price of $111.71 and a 200-day moving average price of $93.09. Revolution Medicines has a 12 month low of $34.00 and a 12 month high of $155.70.

Analysts Set New Price Targets

Several brokerages have recently commented on RVMD. HC Wainwright reaffirmed a "buy" rating on shares of Revolution Medicines in a research report on Wednesday, April 22nd. Benchmark reaffirmed an "overweight" rating on shares of Revolution Medicines in a research report on Tuesday, February 17th. Evercore reaffirmed an "outperform" rating on shares of Revolution Medicines in a research report on Tuesday, April 14th. UBS Group assumed coverage on shares of Revolution Medicines in a research report on Friday, February 27th. They set a "buy" rating for the company. Finally, Stifel Nicolaus reissued a "buy" rating on shares of Revolution Medicines in a research report on Monday, April 20th. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $78.94.

Insider Activity at Revolution Medicines

In other news, insider Stephen Michael Kelsey sold 4,302 shares of the business's stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $427,962.96. Following the completion of the sale, the insider directly owned 295,398 shares of the company's stock, valued at $29,386,193.04. The trade was a 1.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Xiaolin Wang sold 2,010 shares of the business's stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $199,954.80. Following the sale, the insider directly owned 116,063 shares of the company's stock, valued at approximately $11,545,947.24. The trade was a 1.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 184,592 shares of company stock valued at $24,499,532 over the last quarter. 8.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RVMD. Nextech Invest Ltd. increased its stake in Revolution Medicines by 20.7% in the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company's stock valued at $332,472,000 after buying an additional 1,304,347 shares during the last quarter. J.W. Cole Advisors Inc. purchased a new position in shares of Revolution Medicines in the 4th quarter worth approximately $216,000. Twinbeech Capital LP purchased a new position in shares of Revolution Medicines in the 4th quarter worth approximately $215,000. Corient Private Wealth LLC purchased a new position in shares of Revolution Medicines in the 4th quarter worth approximately $215,000. Finally, US Bancorp DE boosted its stake in shares of Revolution Medicines by 170.3% in the 3rd quarter. US Bancorp DE now owns 3,168 shares of the company's stock worth $148,000 after buying an additional 1,996 shares during the last quarter. 94.34% of the stock is currently owned by hedge funds and other institutional investors.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.